UPenn study of CRISPR/Cas9 cell therapy in cancers doses first patients
NPR reported that the two patients, one with multiple myeloma and one with sarcoma, had received the gene-edited cell therapy as part of a Phase I trial.
How Philly can grow the next generation of leading biotech startups
A conversation with investor Gary Kurtzman.
The New Blueprint: How Clever Care Health Plan is Scaling Its Member Experience [Video]
MedCity News was at the Vive conference and spoke with executives who shared their insights for the healthcare industry.